An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
NCT03002376
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
47
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
REGN2810
Sponsor
Regeneron Pharmaceuticals
Collaborators
[object Object]